Global Cancer Monoclonal Antibodies Market Growth 2025-2031
Description
The global Cancer Monoclonal Antibodies market size is predicted to grow from US$ 43230 million in 2025 to US$ 74530 million in 2031; it is expected to grow at a CAGR of 9.5% from 2025 to 2031.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
The mAbs, which are produced by genetic engineering, target antigens in cells, tissues, and organs. They are used in clinical applications to treat diseases with excellent efficacy and minimal side effects. Their MOA, absence of generic pathway, and therapeutic applications distinguish them from other targeted therapeutics.
Cancer is one of the leading causes of death globally. There were 10.9 million new cases, in 2002, which increased to 14.1 million, in 2012 (approximately 30% growth in a decade). The WHO expects this number to increase by 70%, over the next two decades. According to the WHO, almost 70% of deaths occur in low and middle-income countries. The increment in data is expected to provide the basis for any national policy on cancer, leading to an increase in the percentage of people choosing cancer treatment. In the healthcare sector, cancer is one of the biggest concerns. Thus, the increased use of monoclonal antibodies for the treatment of cancer is driving this market.
LP Information, Inc. (LPI) ' newest research report, the “Cancer Monoclonal Antibodies Industry Forecast” looks at past sales and reviews total world Cancer Monoclonal Antibodies sales in 2024, providing a comprehensive analysis by region and market sector of projected Cancer Monoclonal Antibodies sales for 2025 through 2031. With Cancer Monoclonal Antibodies sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Cancer Monoclonal Antibodies industry.
This Insight Report provides a comprehensive analysis of the global Cancer Monoclonal Antibodies landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Cancer Monoclonal Antibodies portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Cancer Monoclonal Antibodies market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cancer Monoclonal Antibodies and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cancer Monoclonal Antibodies.
This report presents a comprehensive overview, market shares, and growth opportunities of Cancer Monoclonal Antibodies market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Murine Antibodies
Chimeric and Humanised Antibodies
Fully Humanized Antibodies
Others
Segmentation by Application:
Liver
Breast
Blood
Brain
Hodgkins and Non-Hodgkins lymphoma
Colorectal
Leukaemia
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
F. Hoffmann-La Roche
Amgen
Bristol-Myers Squibb
Takeda Pharmaceuticals
Key Questions Addressed in this Report
What is the 10-year outlook for the global Cancer Monoclonal Antibodies market?
What factors are driving Cancer Monoclonal Antibodies market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Cancer Monoclonal Antibodies market opportunities vary by end market size?
How does Cancer Monoclonal Antibodies break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
The mAbs, which are produced by genetic engineering, target antigens in cells, tissues, and organs. They are used in clinical applications to treat diseases with excellent efficacy and minimal side effects. Their MOA, absence of generic pathway, and therapeutic applications distinguish them from other targeted therapeutics.
Cancer is one of the leading causes of death globally. There were 10.9 million new cases, in 2002, which increased to 14.1 million, in 2012 (approximately 30% growth in a decade). The WHO expects this number to increase by 70%, over the next two decades. According to the WHO, almost 70% of deaths occur in low and middle-income countries. The increment in data is expected to provide the basis for any national policy on cancer, leading to an increase in the percentage of people choosing cancer treatment. In the healthcare sector, cancer is one of the biggest concerns. Thus, the increased use of monoclonal antibodies for the treatment of cancer is driving this market.
LP Information, Inc. (LPI) ' newest research report, the “Cancer Monoclonal Antibodies Industry Forecast” looks at past sales and reviews total world Cancer Monoclonal Antibodies sales in 2024, providing a comprehensive analysis by region and market sector of projected Cancer Monoclonal Antibodies sales for 2025 through 2031. With Cancer Monoclonal Antibodies sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Cancer Monoclonal Antibodies industry.
This Insight Report provides a comprehensive analysis of the global Cancer Monoclonal Antibodies landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Cancer Monoclonal Antibodies portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Cancer Monoclonal Antibodies market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cancer Monoclonal Antibodies and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cancer Monoclonal Antibodies.
This report presents a comprehensive overview, market shares, and growth opportunities of Cancer Monoclonal Antibodies market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Murine Antibodies
Chimeric and Humanised Antibodies
Fully Humanized Antibodies
Others
Segmentation by Application:
Liver
Breast
Blood
Brain
Hodgkins and Non-Hodgkins lymphoma
Colorectal
Leukaemia
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
F. Hoffmann-La Roche
Amgen
Bristol-Myers Squibb
Takeda Pharmaceuticals
Key Questions Addressed in this Report
What is the 10-year outlook for the global Cancer Monoclonal Antibodies market?
What factors are driving Cancer Monoclonal Antibodies market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Cancer Monoclonal Antibodies market opportunities vary by end market size?
How does Cancer Monoclonal Antibodies break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
75 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Global by Company
- 4 World Historic Review for Cancer Monoclonal Antibodies by Geographic Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Manufacturing Cost Structure Analysis
- 11 Marketing, Distributors and Customer
- 12 World Forecast Review for Cancer Monoclonal Antibodies by Geographic Region
- 13 Key Players Analysis
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
